title: Platelet hypoaggregability in hereditary hypertriglyceridemic rats: relation to plasma triglycerides.
abstract: To define better the relationships between lipid metabolism disturbances and platelet aggregation we have examined these parameters in hereditary hypertriglyceridemic and control Lewis rats. Hereditary hypertriglyceridemic rats are hypertensive and have high plasma triglycerides but not elevated plasma total cholesterol. In the present study, we have demonstrated that platelets from hereditary hypertriglyceridemic rats have lowered initial rate and maximal aggregation after stimulation with thrombin or ADP in comparison with controls. These two strains did not differ significantly in the inhibition of platelet aggregation by the thromboxane A2 receptor inhibitor, SQ 29 548. In hereditary hypertriglyceridemic rats, the thrombin response, as well as the contribution of the thromboxane A2-sensitive pathway, were positively associated with the plasma level of triglycerides. Similar trend was found in Lewis rats. However, the slopes of these relationships were reduced in hereditary hypertriglyceridemic rats. These alterations of the aggregatory responses in hereditary hypertriglyceridemic rats were independent of blood pressure and plasma cholesterol level. In conclusion, our results showed a clear-cut platelet hypoaggregability to both thrombin and ADP in hypertensive hypertriglyceridemic rats. This hypoaggregability was not due to an impaired function of the thromboxane A2 pathway but could be connected with disturbances of lipid metabolism.
authors.affiliation: Institute of Physiology, Academy of Sciences of the Czech Republic, Prague. Kunes@Sun1.biomed.cas.cz
authors.forename: J
authors.initials: J
authors.lastname: Kunes
authors.forename: M M
authors.initials: MM
authors.lastname: Mazeaud
authors.forename: M A
authors.initials: MA
authors.lastname: Devynck
authors.forename: J
authors.initials: J
authors.lastname: Zicha
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines / Q000494:pharmacology; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000235:genetics; D015228:Hypertriglyceridemia / Q000097:blood* / Q000150:complications / Q000235:genetics*; D007700:Kinetics; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D051381:Rats; D011917:Rats, Inbred Lew; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D013917:Thrombin / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood*
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D017482:Receptors, Thromboxane; D014280:Triglycerides; D000244:Adenosine Diphosphate; C045749:SQ 29548; D013917:Thrombin